Johnson & Johnson immediately made it presence felt at this year’s J.P. Morgan Healthcare Conference in San Francisco by announcing its latest $2bn bet on the antibody-drug conjugates through its acquisition of Ambrx Biopharma.
JPM 2024: Intuitive And J&J Both Weigh In On Growth For 2024
The two medtech giants – both of which will soon be releasing new robotic systems – spoke about growth targets and opportunities going into 2024.
